Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GIST-TEN: Imatinib Maintenance vs Interruption After ≥10 Years in Advanced/Metastatic GIST
2024-512631-77-00Phase 2Authorised
- Sponsor
- Centre Léon Bérard
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of imatinib in gastrointestinal stromal tumor (GIST) (2 arms), sponsored by Centre Léon Bérard. Primary endpoint: Progression-free rate at 6 months. Planned start Aug 2024; status: authorised.
02
Drugs
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on 2024-512631-77-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512631-77-00.